Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism

Blood (2023) 142 (Supplement 1): 2952.

https://doi.org/10.1182/blood-2023-186514

Published: 2023

Journal Articles

Lipophagy As a Mechanism of Resistance in T-ALL Following Energetic Crisis Induced By Oxphos/MCT1 Blockade: Strategies to Eradicate Residual Disease

Natalia Baran, Shraddha Patel, Cassandra L Ramage, Alessia Lodi, Jose Enriquez Ortiz, Yogesh Dhungana, Meghan Collins, Anna Skwarska, Connie Weng, Kala Hayes, Zhihong Zeng, Laurie Cooper, Richard Eric Davis, Gheath Alatrash, Joseph R Marszalek, Jiyang Yu, Pratip K Bhattacharya, Stefano Tiziani, Marina Konopleva

Blood (2022) 140 (Supplement 1): 8831–8832.

https://doi.org/10.1182/blood-2022-170713

Published: 2022

Journal Articles

Accumulation of Intracellular L-Lactate and Irreversible Disruption of Mitochondrial Membrane Potential upon Dual Inhibition of Oxphos and Lactate Transporter MCT-1 Induce Synthetic Lethality in T-ALL Via Mitochondrial Exhaustion

Natalia Baran, Shraddha Patel, Alessia Lodi, Jose Enriquez Ortiz, Yogesh Dhungana, Meghan Collins, Anna Skwarska, Connie Weng, Cassandra L Ramage, Kala Hayes, Zhihong Zeng, Eric Davis, Gheath Alatrash, Joseph R Marszalek, Jiyang Yu, Pratip K Bhattacharya, Stefano Tiziani, Marina Konopleva

Blood (2021) 138 (Supplement 1): 680.

https://doi.org/10.1182/blood-2021-152845

Published: 2021

Journal Articles

Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models

Qi Zhang, PhD, Lina Han, PhD, Alessia Lodi, PhD, Connie Weng, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, MSc, Helen Ma, MS, Abhishek Maiti, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142547

Published: 2020

Journal Articles

The Combined Treatment with the FLT3-Inhibitor AC220 and the Complex I Inhibitor Iacs-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells

Xiyuan Lu, Alessia Lodi, PhD, Lina Han, PhD, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD, Stefano Tiziani, PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141986

Published: 2020

Journal Articles

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Yoko Tabe, MD PhD, Kaori Saito, Kotoko Yamatani, MD, Haeun Yang, Rodrigo Jacamo, PhD, Helen Ma, MS, Vivian Ruvolo, MS, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Natalia Baran, PhDMD, Junichi Imoto, Kazuho Ikeo, PhD, Koya Suzuki, PhD, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Christopher P Vellano, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-137366

Published: 2020

Journal Articles

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Natalia Baran, PhDMD, Alessia Lodi, PhD, Yogesh Dhungana, PhD, Shannon RENEE Sweeney, PhD, Pandey Renu, PhD, Shelley Herbrich, PhD, Fieke W Hoff, BSc, Anna Skwarska, PhD, Mecit Kaplan, MS, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, MSc, Marc Warmoes, PhD, Shanti Rojas-Sutterlin, PhD, Andre Haman, PhD, Diogo Troggian Veiga, PhD, Ken Furudate, DDM, PhD, Helen Ma, MS, Karine Harutyunyan, PhD, Wentao Yang, Mihai Gagea, MDPhD, Di Du, PhD, May Daher, Luciana Melo Garcia, MD, Sujan Piya, PhD, Vivian Ruvolo, MS, Sriram Shanmugavelandy, Ningping Feng, PhD, Jason P Gay, MS, Ondrej Havranek, MDPhD, Jared Henderson, MS, Katarzyna Tomczak, PhD, Marcin Kaminski, PhD, Daniel Herranz, PharmD, Adolfo Ferrando, MD, PhD, Elias Jabbour, MD, Maria E Di Francesco, PhD, David T. Teachey, MD, Terzah M. Horton, MD PhD, Katayoun Rezvani, MD PhD, Jun J. Yang, PhD, Steven M. Kornblau, MD, Eric Davis, MD, Koichi Takahashi, MD PhD, Michael Andreeff, MD PhD, Joseph R Marszalek, PhD, Philip Lorenzi, PhD, Jiyang Yu, PhD, Stefano Tiziani, PhD, Trang Hoang, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-136801

Published: 2020

Journal Articles

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Qi Zhang, PhD, Alessia Lodi, PhD, Shannon Renee Sweeney, PhD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, Helen Ma, MS, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3927.

https://doi.org/10.1182/blood-2019-124494

Published: 2019

Journal Articles

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Lina Han, PhD, Antonio Cavazos, Natalia Baran, PhDMD, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Jason P Gay, MS, Ningping Feng, PhD, Venkata Lokesh Battula, PhD, Hagop M. Kantarjian, MD, Naval G. Daver, MD, Joseph R Marszalek, PhD, Michael Andreeff, MD PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 5161.

https://doi.org/10.1182/blood-2019-124475

Published: 2019

Journal Articles

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Blood (2019) 134 (Supplement_1): 806.

https://doi.org/10.1182/blood-2019-128930

Published: 2019

Journal Articles

A Novel Patient-Derived Xenograft Model of Secondary CD20 - CNS Lymphoma for Mechanistic and Therapeutic Exploration

Liang Zhang, MD PhD, Hui Zhang, Hui Guo, PhD, Yuting Sun, PhD, Ningping Feng, PhD, Joseph R Marszalek, PhD, Makhdum Ahmed, MDPhDMPH, Krystle Nomie, PhD, Michael Wang, MD

Blood (2018) 132 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2018-99-112205

Published: 2018

Journal Articles

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Blood (2018) 132 (Supplement 1): 4020.

https://doi.org/10.1182/blood-2018-99-117310

Published: 2018

Journal Articles

Mitochondrial Transfer Confers Microenvironment-Mediated Resistance to Oxphos Inhibition in AML

Haeun Yang, Yoko Tabe, MD PhD, Kaori Saito, Rodrigo Jacamo, PhD, Helen Ma, MS, Vivian Ruvolo, MS, Junichi Imoto, Kazuho Ikeo, PhD, Kaoru Mogushi, PhD, Masaki Hosoya, PhD, Shigeo Yamaguchi, Kotoko Yamatani, MD, Yuko Murakami-Tonami, MD, Koya Suzuki, PhD, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Joseph R Marszalek, PhD, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 430.

https://doi.org/10.1182/blood-2018-99-112933

Published: 2018

Journal Articles

Inhibition of Oxphos with Iacs-010759 Depletes AML Leukemia Initiating Cells (LIC) in Vitro and Improves Survival in Pre-Clinical AML Models

Blood (2017) 130 (Supplement 1): 1350.

https://doi.org/10.1182/blood.V130.Suppl_1.1350.1350

Published: 2017

Journal Articles

BCL-2 Antagonist ABT-199 Combined with Complex I Inhibitor IACS-010759 Blocks Mitochondrial Respiration and Facilitates Anti-Leukemia Efficacy in Pre-Clinical AML Models

Qi Zhang, PhD MD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, Antonio Cavazos, MSc, Helen Ma, MS, Venkata Lokesh Battula, PhD, Natalia Baran, PhD MD, Karine Harutyunyan, PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 1362.

https://doi.org/10.1182/blood.V130.Suppl_1.1362.1362

Published: 2017

Journal Articles

Novel Oxidative Phosphorylation Inhibitor IACS-010759 Induces AMPK-Dependent Apoptosis of AML Cells

Haeun Yang, Yoko Tabe, MD PhD, Kazumasa Sekihara, PhD, Kaori Saito, Helen Ma, MS, Vivian Ruvolo, PhD, Junichi Imoto, Kazuho Ikeo, PhD, Kaoru Mogushi, PhD, Masaki Hosoya, Yoshihide Hayashizaki, MD PhD, Yasunari Yamanaka, MD PhD, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 1245.

https://doi.org/10.1182/blood.V130.Suppl_1.1245.1245

Published: 2017

Journal Articles

Targeting Residual Chemotherapy-Resistant Acute Myeloid Leukemia Cells By a Novel Oxphos Inhibitor IACS010759

Lina Han, PhD, Antonio Cavazos, MSc, Natalia Baran, PhD MD, Qi Zhang, PhD MD, Vinitha Mary Kuruvilla, Jason P Gay, MS, Ningping Feng, PhD, Venkata Lokesh Battula, PhD, Michael Andreeff, MD PhD, Hagop M. Kantarjian, MD, Naval Daver, MD, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 2623.

https://doi.org/10.1182/blood.V130.Suppl_1.2623.2623

Published: 2017

Journal Articles

Mitochondrial Complex I Inhibition with Iacs-010759 in T-ALL Preclinical Models

Natalia Baran, PhD, Jennifer Molina, PhD, Antonio Cavazos, MS, Karine Harutyunyan, PhD, Ningping Feng, PhD, Jason Gay, MS, Sujan Piya, PhD, Sriram Shanmuga Velandy, MS, Elias J. Jabbour, MD, Michael Andreeff, MD PhD, Stefano Tiziani, PhD, Adolfo A. Ferrando, MD PhD, Patrick Zweidler-McKay, MD PhD, M. Emilia Di Francesco, PhD, Joseph R. Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 4028.

https://doi.org/10.1182/blood.V128.22.4028.4028

Published: 2016

Journal Articles

Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

Byung-Sik Cho, Zhihong Zeng, Hong Mu, Zhiqiang Wang, Sergej Konoplev, Teresa McQueen, Marina Protopopova, Jorge Cortes, Joseph R. Marszalek, Sheng-Bin Peng, Wencai Ma, R. Eric Davis, Donald E. Thornton, Michael Andreeff, Marina Konopleva

Blood (2015) 126 (2): 222–232.

https://doi.org/10.1182/blood-2015-02-628677

Published: 2015

Includes: Supplemental data

NARROW

Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism

Lipophagy As a Mechanism of Resistance in T-ALL Following Energetic Crisis Induced By Oxphos/MCT1 Blockade: Strategies to Eradicate Residual Disease

Accumulation of Intracellular L-Lactate and Irreversible Disruption of Mitochondrial Membrane Potential upon Dual Inhibition of Oxphos and Lactate Transporter MCT-1 Induce Synthetic Lethality in T-ALL Via Mitochondrial Exhaustion

Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models

The Combined Treatment with the FLT3-Inhibitor AC220 and the Complex I Inhibitor Iacs-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

A Novel Patient-Derived Xenograft Model of Secondary CD20 - CNS Lymphoma for Mechanistic and Therapeutic Exploration

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Mitochondrial Transfer Confers Microenvironment-Mediated Resistance to Oxphos Inhibition in AML

Inhibition of Oxphos with Iacs-010759 Depletes AML Leukemia Initiating Cells (LIC) in Vitro and Improves Survival in Pre-Clinical AML Models

BCL-2 Antagonist ABT-199 Combined with Complex I Inhibitor IACS-010759 Blocks Mitochondrial Respiration and Facilitates Anti-Leukemia Efficacy in Pre-Clinical AML Models

Novel Oxidative Phosphorylation Inhibitor IACS-010759 Induces AMPK-Dependent Apoptosis of AML Cells

Targeting Residual Chemotherapy-Resistant Acute Myeloid Leukemia Cells By a Novel Oxphos Inhibitor IACS010759

Mitochondrial Complex I Inhibition with Iacs-010759 in T-ALL Preclinical Models

Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only